Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/9185Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Tsimihodimos, V. | en |
| dc.contributor.author | Kostapanos, M. | en |
| dc.contributor.author | Kostara, C. | en |
| dc.contributor.author | Balraktari, E. T. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T16:47:27Z | - |
| dc.date.available | 2015-11-24T16:47:27Z | - |
| dc.identifier.issn | 1734-1922 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/9185 | - |
| dc.rights | Default Licence | - |
| dc.subject | metabolic syndrome | en |
| dc.subject | apolipoprotein c-ii | en |
| dc.subject | apolipoprotein c-iii | en |
| dc.subject | small dense ldl | en |
| dc.subject | triglycerides | en |
| dc.subject | obesity | en |
| dc.subject | coronary-heart-disease | en |
| dc.subject | lipoprotein-lipase | en |
| dc.subject | a-i | en |
| dc.subject | triglyceride levels | en |
| dc.subject | endothelial-cells | en |
| dc.subject | apoc-iii | en |
| dc.subject | hypertriglyceridemic subjects | en |
| dc.subject | micronized fenofibrate | en |
| dc.subject | cardiovascular risk | en |
| dc.subject | phospholipase a(2) | en |
| dc.title | Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | <Go to ISI>://000262198500009 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Introduction: Apolipoprotein (apo) C-II is considered as an important activator of lipoprotein lipase (LPL) and is required for efficient lipolysis of triglyceride (TG)-rich lipoproteins. In contrast, excess apo C-II inhibits LPL-mediated hydrolysis of TGs. Apo C-III is an inhibitor of LPL activity. These effects may influence the plasma levels of atherogenic small dense low-density lipoprotein cholesterol (sdLDL-C), since TG concentrations are markers of this subfraction. Material and methods: We examined the possible influence of apo C-II and C-III plasma levels or sdLDL-C concentration in obese patients with metabolic syndrome (MetS). Plasma apo C-II and C-III were determined by an immunoturbidimetric assay. Obese subjects (n=73) with MetS but without any clinically evident cardiovascular disease were enrolled. Results: TG, apo C-II and C-III plasma levels progressively increased when study participants were divided according to sdLDL-C tertiles (P < 0.001 for all 3 trends). The apo C-III/C-II ratio was relatively constant (i.e. approximate to 2.5) for all tertiles of SdLDL-C. Stepwise multiple linear regression analyses showed that apo C-III levels independently correlated with TG levels, while TG and apo B levels were independently associated with sdLDL-C concentrations. Apo C-II and C-III significantly correlated with sdLDL-C in univariate analysis, but not in multivariate analysis. Conclusions: Apo C-II and C-III levels are not independent predictors of sdLDL-C levels in obese subjects with MetS. | en |
| heal.journalName | Archives of Medical Science | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
